Diadem has secured the CE-IVD Mark for its AlzoSure Predict blood test for Alzheimer's disease, paving the way for its introduction in Europe and the U.K.
The prognostic blood test can predict likely progression to Alzheimer's disease up to six years in advance of symptoms, according to the company. AlzoSure previously received breakthrough device designation by the U.S. Food and Drug Administration (FDA) in January.
